A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites.
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2012
At a glance
- Drugs Aflibercept (Primary)
- Indications Malignant ascites; Ovarian cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 20 Dec 2011 Results published in Lancet Oncology.
- 17 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History